LRMR Larimar Therapeutics
- 4.160
- -0.160-3.70%
- 4.110
- -0.050-1.20%
Larimar Therapeutics News
Baird Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $13
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely
A Quick Look at Today's Ratings for Larimar Therapeutics(LRMR.US), With a Forecast Between $14 to $36
12 Health Care Stocks Moving In Monday's Pre-Market Session
Analyst Recommends Buy on Larimar Therapeutics Amid Misinterpreted Data and Overreaction
Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR) and Ascendis Pharma (ASND)
Crude Oil Down 1%; Webuy Global Shares Spike Higher
Why Is Larimar Therapeutics Stock Trading Lower On Monday?
Promising Developments and Strategic Regulatory Support Justify Buy Rating for Larimar Therapeutics
Express News | HC Wainwright & Co. Reiterates Buy on Larimar Therapeutics, Maintains $15 Price Target
Larimar Therapeutics Selloff a Buying Opportunity, Says JonesResearch
Larimar Therapeutics Analyst Ratings
Larimar Therapeutics Stock Plunges on Clinical Study Concerns
Express News | Larimar Therapeutics Shares Resume Trade
Express News | Larimar Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -41.8%
Express News | Larimar Therapeutics Inc: Projected Runway Into Q2 of 2026
Express News | Larimar Therapeutics Inc - Bla Submission Targeted for 2H 2025 for Potential Accelerated Approval
Express News | Larimar Therapeutics Inc - Nomlabofusp 25 Mg Well Tolerated in 14 Participants for up to 260 Days
Larimar Therapeutics Reports Data From Rare Disease Drug Study
No Data